Rossari Biotech

What does Rossari Biotech do?

Rossari Biotech Ltd is a small-cap company in the specialty chemicals industry, founded in 2003 and converted to a corporate entity in 2009. As of March 2025, it reported net sales of ₹580 Cr and a net profit of ₹34 Cr, with a market cap of ₹3,813 Cr.

Overview: <BR>Rossari Biotech Ltd operates in the specialty chemicals industry and is classified as a small-cap company.<BR><BR>History: <BR>Rossari Biotech Limited was founded in 2003 as a partnership firm named Rossari Labtech and was established by Mr. Edward Walter Menezes and Mr. Sunil Srinivasan Chari. The company was renamed to Rossari Biotech Limited and converted into a corporate entity in 2009. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 580 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 34 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 3,813 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 28.00 <BR>Industry P/E: 47 <BR>Dividend Yield: 0.07% <BR>Debt-Equity: 0.09 <BR>Return on Equity: 11.50% <BR>Price to Book: 3.21 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are in the management team of Rossari Biotech?

As of March 2023, the management team of Rossari Biotech includes Sunil Chari (Managing Director), Edward Menezes (Chairman & Executive Director), and several independent directors, along with key roles such as Company Secretary and Additional Directors, all contributing to the company's governance and strategy.

As of March 2023, the management team of Rossari Biotech includes the following individuals:<BR><BR>1. Sunil Chari - Managing Director<BR>2. Edward Menezes - Chairman & Executive Director<BR>3. Goutam Bhattacharya - Non-Executive & Independent Director<BR>4. Aseem Dhru - Non-Executive & Independent Director<BR>5. Sharabh Pachory - Non-Executive & Independent Director<BR>6. Parul Gupta - Company Secretary & Compliance Officer<BR>7. Aparna Narendra Sharma - Additional Independent Director<BR>8. Esha Padmanabhan Achan - Additional Director<BR><BR>This team plays a crucial role in the governance and strategic direction of the company.

Has Rossari Biotech declared dividend?

Yes, Rossari Biotech Ltd has declared a 25% dividend, amounting to ₹0.5 per share, with an ex-date of August 16, 2024. However, the company's total returns over various periods have been largely negative, particularly in the longer term.

Rossari Biotech Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 0.5<BR>- Ex-date: 16 Aug 24<BR><BR>Dividend Yield: 0.07%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -16.15%, with no dividend return, resulting in a total return of -16.15%.<BR><BR>Over the past year, the price return was 1.18%, with a dividend return of 0.07%, leading to a total return of 1.25%.<BR><BR>In the 2-year period, the price return was -14.66%, with a dividend return of 0.06%, resulting in a total return of -14.6%.<BR><BR>For the 3-year period, the price return was -22.58%, with a dividend return of 0.17%, leading to a total return of -22.41%.<BR><BR>In the 4-year period, the price return was -45.59%, with a dividend return of 0.16%, resulting in a total return of -45.43%.<BR><BR>Over the last 5 years, there was no price return and no dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, while Rossari Biotech has declared a dividend, the total returns over various periods indicate a challenging performance, particularly in longer time frames, with significant negative price returns.

Is Rossari Biotech overvalued or undervalued?

As of May 21, 2025, Rossari Biotech is considered very attractive and undervalued, with a PE ratio of 27.86, an EV to EBITDA of 14.73, and a ROCE of 15.36%, despite a year-to-date return of -12.35% compared to the Sensex's 5.58%.

As of 21 May 2025, the valuation grade for Rossari Biotech has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued. Key ratios include a PE ratio of 27.86, an EV to EBITDA of 14.73, and a ROCE of 15.36%. <BR><BR>In comparison to its peers, Rossari Biotech's PE ratio is similar to that of its closest competitor, which also shows a PE of approximately 27.86, while the industry average EV to EBITDA is lower, suggesting that Rossari may have a competitive edge in profitability. Despite recent underperformance relative to the Sensex, with a year-to-date return of -12.35% compared to the Sensex's 5.58%, the company's strong fundamentals and attractive valuation metrics support the conclusion that it is undervalued in the current market.

Who are the peers of the Rossari Biotech?

Peers of Rossari Biotech include Balaji Amines, Styrenix Perfor., Camlin Fine, Laxmi Organic, Neogen Chemicals, Vishnu Chemicals, S H Kelkar & Co., Foseco India, Nocil, and Fineotex Chem. Rossari Biotech has average growth and good management risk, with a 1-year return of -10.65%.

Peers: The peers of Rossari Biotech are Balaji Amines, Styrenix Perfor., Camlin Fine, Laxmi Organic, Neogen Chemicals, Vishnu Chemicals, S H Kelkar & Co., Foseco India, Nocil, and Fineotex Chem.<BR><BR>Quality Snapshot: Excellent management risk is observed at Styrenix Perfor. and Foseco India, while Good management risk is found at Neogen Chemicals, Rossari Biotech, Vishnu Chemicals, and Fineotex Chem. Average management risk is noted at Balaji Amines, Laxmi Organic, and S H Kelkar & Co., and the rest have Below Average management risk. Growth is Good at Styrenix Perfor. and Vishnu Chemicals, Average at Rossari Biotech and Fineotex Chem, and Below Average at Balaji Amines, Camlin Fine, Laxmi Organic, Neogen Chemicals, S H Kelkar & Co., Foseco India, and Nocil. Excellent capital structure is seen in Balaji Amines, Styrenix Perfor., Laxmi Organic, Foseco India, and Nocil, while Good capital structure is found at Vishnu Chemicals and S H Kelkar & Co., and the rest have Below Average capital structure.<BR><BR>Return Snapshot: Camlin Fine has the highest 1-year return at 141.62%, while Nocil has the lowest at -37.94%. Rossari Biotech's 1-year return is -10.65%, which is higher than Nocil's but lower than Camlin Fine's. Additionally, Laxmi Organic, Neogen Chemicals, Nocil, and Fineotex Chem have negative six-month returns.

Who are the top shareholders of the Rossari Biotech?

The top shareholders of Rossari Biotech include promoter Edward Menezes with 29.11%, mutual funds holding 13.42%, foreign institutional investors at 3.48%, and individual investors owning 9.44%. The largest public shareholder is Uti-flexi Cap Fund with 6.04%.

The top shareholders of Rossari Biotech include the promoters, who hold the majority of the shares. Edward Menezes is the promoter with the highest holding at 29.11%. Additionally, mutual funds collectively hold 13.42% of the shares across 8 schemes, while foreign institutional investors (FIIs) hold 3.48% through 52 different entities. The highest public shareholder is Uti-flexi Cap Fund, which holds 6.04%. Individual investors collectively own 9.44% of the company.

How big is Rossari Biotech?

As of 24th July, Rossari Biotech Ltd has a market capitalization of 3,990.00 Cr, with recent Net Sales of 2,134.36 Cr and a Net Profit of 135.07 Cr. The company reported Shareholder's Funds of 1,185.45 Cr and Total Assets of 1,885.67 Cr for the period ending March 2025.

As of 24th July, Rossari Biotech Ltd has a market capitalization of 3,990.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Rossari Biotech reported Net Sales of 2,134.36 Cr and a Net Profit of 135.07 Cr.<BR><BR>For the reporting period ending March 2025, the company had Shareholder's Funds amounting to 1,185.45 Cr and Total Assets of 1,885.67 Cr.

When is the next results date for Rossari Biotech?

Rossari Biotech will announce its results on 15 October 2025.

Rossari Biotech will declare its results on 15 October 2025.

Are Rossari Biotech latest results good or bad?

Rossari Biotech's latest results show strong revenue growth of 17.61% year-on-year, but profitability concerns arise from a declining operating margin of 12.27%. While net profit increased, the stock has underperformed, declining 22.84% over the past year, indicating potential sustainability issues in earnings growth.

Rossari Biotech's latest results present a mixed picture. On the positive side, the company achieved a notable revenue growth of 17.61% year-on-year, with net sales reaching ₹586.11 crores, marking the highest quarterly revenue in its recent history. Additionally, net profit increased by 3.91% year-on-year to ₹36.41 crores, and there was a sequential improvement in net profit of 10.07% compared to the previous quarter.<BR><BR>However, there are significant concerns regarding profitability. The operating margin has contracted to 12.27%, down from 13.23% in the same quarter last year, indicating rising cost pressures. This margin compression suggests that while revenue is growing, the company is struggling to convert that growth into profit effectively. The market has reacted cautiously, with the stock declining 22.84% over the past year, significantly underperforming the broader market.<BR><BR>In summary, while Rossari Biotech demonstrates strong revenue growth, the challenges with operating margins and profitability raise concerns about the sustainability of its earnings growth. Investors may need to watch for improvements in margin stability and overall profitability in the upcoming quarters.

How has been the historical performance of Rossari Biotech?

Rossari Biotech has demonstrated consistent growth in net sales and profits, with net sales increasing from INR 600.09 crore in March 2020 to INR 2,080.29 crore in March 2025, and profit after tax rising from INR 65.47 crore to INR 135.40 crore during the same period. The company's earnings per share improved from INR 12.86 to INR 24.64, reflecting enhanced shareholder value.

Answer:<BR>The historical performance of Rossari Biotech shows a consistent growth trajectory in net sales and profits over the past several years.<BR><BR>Breakdown:<BR>Rossari Biotech's net sales have increased significantly from INR 600.09 crore in March 2020 to INR 2,080.29 crore in March 2025, reflecting a robust annual growth trend. The total operating income followed a similar pattern, rising from INR 600.09 crore in March 2020 to INR 2,080.29 crore in March 2025. The company's operating profit (PBDIT) also demonstrated a positive trend, growing from INR 108.46 crore in March 2020 to INR 269.08 crore in March 2025. Profit before tax increased from INR 88.06 crore in March 2020 to INR 184.21 crore in March 2025, while profit after tax rose from INR 65.47 crore to INR 135.40 crore during the same period. The earnings per share (EPS) improved from INR 12.86 in March 2020 to INR 24.64 in March 2025, indicating enhanced shareholder value. On the balance sheet, total assets grew from INR 471.46 crore in March 2020 to INR 1,885.67 crore in March 2025, with total liabilities increasing from INR 471.46 crore to INR 1,885.67 crore as well. The cash flow from operating activities saw a notable rise from INR 56 crore in March 2020 to INR 137 crore in March 2025, while the net cash inflow turned positive at INR 19 crore in March 2025, compared to a negative outflow in previous years. Overall, Rossari Biotech has shown strong financial performance and growth across multiple metrics over the years.

Is Rossari Biotech technically bullish or bearish?

As of December 2, 2025, Rossari Biotech's trend is mildly bearish, indicated by bearish MACD and moving averages, mixed RSI signals, and mildly bearish Bollinger Bands, suggesting a cautious outlook.

As of 2 December 2025, the technical trend for Rossari Biotech has changed from bearish to mildly bearish. The current stance is mildly bearish with key indicators driving this assessment being the MACD on both the weekly and monthly time frames, which remain bearish, and the daily moving averages also indicating a bearish trend. The RSI shows a bullish signal on the monthly but no signal on the weekly, suggesting mixed momentum. Bollinger Bands are mildly bearish on both weekly and monthly charts, while KST indicates a mildly bullish stance on the weekly but bearish on the monthly. Overall, the lack of definitive bullish signals and the presence of bearish indicators suggest a cautious outlook.

Should I buy, sell or hold Rossari Biotech Ltd?

Which are the latest news on Rossari Biotech?

Why is Rossari Biotech Ltd falling/rising?

As of 19-Jan, Rossari Biotech Ltd's stock price is falling, currently at 520.00, reflecting a decline of -14.65 (-2.74%). The stock has consistently underperformed, reaching a new 52-week low and showing significant declines over various time frames, indicating deteriorating financial health and bearish sentiment among investors.

As of 19-Jan, Rossari Biotech Ltd's stock price is falling, currently at 520.00, reflecting a change of -14.65 (-2.74%). The stock has been on a downward trend, having lost value for the last five consecutive days, resulting in an overall decline of -8.11% during this period. Additionally, the stock has underperformed against the sector by -2.26% today and has reached a new 52-week low of Rs. 519.9.<BR><BR>The stock's performance over various time frames shows significant underperformance compared to the benchmark Sensex. Over the past week, the stock has decreased by -5.95%, and over the last month, it has fallen by -8.70%. Year-to-date, the decline stands at -10.33%, and over the past year, the stock has plummeted by -35.57%, while the Sensex has gained +8.65%. This consistent underperformance highlights a troubling trend for investors.<BR><BR>Moreover, the company's financial metrics reveal weaknesses, particularly in its operating profit to interest ratio, which is at its lowest point of 8.98 times, and a return on capital employed (ROCE) of 12.97%, which is also the lowest recorded. The debt-equity ratio has increased to 0.28 times, indicating rising leverage concerns. Although the company has a low debt-to-equity ratio overall, these recent figures suggest deteriorating financial health.<BR><BR>Despite some positive factors, such as a low debt-to-equity ratio and rising investor participation, the negative results and consistent underperformance against benchmarks have contributed to the stock's decline. The overall sentiment appears to be bearish, leading to the current falling price of Rossari Biotech Ltd.